CORCEPT THERAPEUTICS INC (CORT)
CORCEPT THERAPEUTICS INC (CORT) from its SEC filings: 2025 revenue $761.4 million (+13% vs the year before), net margin 13%, free cash flow $141.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $761.4 million |
| Revenue growth | +13% |
| Net income | $99.7 million |
| Net margin | 13.1% |
| Free cash flow | $141.8 million |
| Diluted EPS | $0.82 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +32% |
| Cash | $111.0 million |
| Long-term debt | $0 |
| Share count, 1 year | +3% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.